Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being developed
as therapeutics and are a major contributor to neutralizing antibody responses elicited …

Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA are frequently observed
in COVID-19. However, it is unclear whether SARS-CoV-2 replicates in the human intestine …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

Background: Patients with chronic inflammatory disease (CID) treated with immunosuppressive
medications have increased risk for severe COVID-19. Although mRNA-based SARS-…

Germinal centres (GC) are lymphoid structures in which B cells acquire affinity-enhancing
somatic hypermutations (SHM), with surviving clones differentiating into memory B cells (MBCs…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

The recent emergence of SARS-CoV-2 variants of concern 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10
and the recurrent spillovers of coronaviruses 11 , 12 into the human population highlight the …